Polatuzumab vedotin (new indication: diffuse large-cell B-cell lymphoma (DLBCL), in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))


  • Active Substance: Polatuzumab vedotin
  • Name: Polivy®
  • Therapeutic area: Diffuse large B-cell lymphoma
  • Pharmaceutical company: Roche Pharma AG

Time table:

  • Start: 01.06.2022
  • Final decision by G-BA: 01.12.2022

Final decision:

  • Hint for a non-quantifiable additional benefit